Claims for Patent: 9,834,539
✉ Email this page to a colleague
Summary for Patent: 9,834,539
Title: | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Abstract: | The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: |
Inventor(s): | Lin Jian, Ericsson Anna, Campbell Ann-Marie, Gustafson Gary, Wang Zhongguo, Diebold R. Bruce, Ashwell Susan, Lancia, Jr. David R., Caravella Justin Andrew, Lu Wei |
Assignee: | FORMA Therapeutics, Inc. |
Application Number: | US14858167 |
Patent Claims: | 2. The compound of claim 1 , wherein A is CN.3. The compound of claim 2 , wherein U is N.4. The compound of claim 1 , wherein A is CN and Ris H claim 1 , C-Calkyl or C-Ccycloalkyl.5. The compound of claim 4 , wherein Ris methyl.6. The compound of claim 1 , wherein A is H or F.7. The compound of claim 1 , wherein Ris H claim 1 , methyl or ethyl.8. The compound of claim 1 , wherein Rand Rare H.9. The compound of claim 1 , wherein Ris H and Ris methyl.10. The compound of claim 1 , wherein Ris H and Ris (S)-methyl.11. The compound of claim 1 , wherein Rand Rare halogen.12. The compound of claim 1 , wherein Ris F and Ris methyl.13. The compound of claim 1 , wherein Rand Rcan combine to form a C-Ccycloalkyl.14. The compound of claim 1 , wherein W claim 1 , W claim 1 , and Ware CH claim 1 , or CF.15. The compound of claim 1 , wherein Wor Wis N.16. The compound of claim 1 , wherein Ris halogen.17. The compound of claim 16 , wherein Ris chloro.18. The compound of claim 1 , wherein Ris H claim 1 , halogen claim 1 , or C-Calkoxy.19. The compound of claim 1 , wherein Ris C-Calkoxy substituted with heteroaryl or 3- to 8-membered heterocyclyl.20. The compound of selected from:5-{[(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)methyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;6-chloro-3-{[(1-ethyl-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-1,2-dihydroquinolin-2-one;6-chloro-3-{[(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-1,2-dihydroquinolin-2-one;5-{[(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)methyl]amino}-6-oxo-1,6-dihydropyridine-2-carbonitrile;6-chloro-3-{[(1-cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-1,2-dihydroquinolin-2-one;6-chloro-3-{[(1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-1,2-dihydroquinolin-2-one;3-{[(6-bromo-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-6-chloro-1,2-dihydroquinolin-2-one;6-chloro-3-({[2-oxo-6-(trifluoromethyl)-1,2-dihydropyridin-3-yl]amino}methyl)-1,2-dihydroquinolin-2-one;6-chloro-3-({[1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridin-3-yl]amino}methyl)-1,2-dihydroquinolin-2-one;6-chloro-7-methoxy-3-{[(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-1,2-dihydroquinolin-2-one;6-chloro-3-{[(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-7-(pyridin-2-ylmethoxy)-1,2-dihydroquinolin-2-one;5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1R)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-7-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyrazine-2-carbonitrile;5-{[(1R)-1-(6-chloro-7-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[1-(6-chloro-7-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-7-methoxy-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1R)-1-(6-chloro-7-methoxy-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[1-(6-chloro-7-methoxy-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-[6-chloro-2-oxo-7-(pyridin-2-ylmethoxy)-1,2-dihydroquinolin-3-yl]ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1R)-1-[6-chloro-2-oxo-7-(pyridin-2-ylmethoxy)-1,2-dihydroquinolin-3-yl]ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-({1-[6-chloro-2-oxo-7-(pyridin-2-ylmethoxy)-1,2-dihydroquinolin-3-yl]ethyl}amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-{6-chloro-2-oxo-7-[(1R)-1-(pyridin-2-yl)ethoxy]-1,2-dihydroquinolin-3-yl}ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-[6-chloro-7-(cyclopropylmethoxy)-2-oxo-1,2-dihydroquinolin-3-yl]ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-[6-chloro-2-oxo-7-(propan-2-yloxy)-1,2-dihydroquinolin-3-yl]ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-8-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1, 6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydro-1, 8-naphthyridin-3-yl)ethyl]amino}-1-methyl-6-oxo-1, 6-dihydropyridine-2-carbonitrile;5-{[(1R)-1-(7-chloro-3-oxo-3,4-dihydroquinoxalin-2-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; or5-{[(1S)-1-(7-chloro-3-oxo-3,4-dihydroquinoxalin-2-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.21. The compound of selected from:5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-6-oxo-1-(trifluoromethyl)-1, 6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-[6-chloro-7-(2-hydroxypropan-2-yl)-2-oxo-1,2-dihydroquinolin-3-yl]ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-7-cyclopropyl-2-oxo-1,2-dihydro-1, 8-naphthyridin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-{6-chloro-7-[(2-hydroxy-2-methylpropyl)amino]-2-oxo-1,2-dihydroquinolin-3-yl}ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-[7-(azetidin-1-yl)-6-chloro-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-[7-(azetidin-1-yl)-6-chloro-2-oxo-1,2-dihydroquinolin-3-yl]ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;6-chloro-3-[(1S)-1-{[1-methyl-2-oxo-6-(1H-1,2,3,4-tetrazol-1-yl)-1,2-dihydropyridin-3-yl]amino}ethyl]-1,2-dihydroquinolin-2-one; or5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carboxamide.27. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.28. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 1 , wherein the disease is glioma claim 1 , glioblastoma multiforme claim 1 , paraganglioma claim 1 , acute myeloid leukemia (AML) claim 1 , prostate cancer claim 1 , thyroid cancer claim 1 , colon cancer claim 1 , chondrosarcoma claim 1 , cholangiocarcinoma claim 1 , peripheral T-cell lymphoma claim 1 , melanoma claim 1 , intrahepatic cholangiocarcinoma (IHCC) claim 1 , myelodysplastic syndrome (MDS) claim 1 , or myeloproliferative disease (MPD).29. The method of claim 28 , wherein the cell proliferative disease is glioma claim 28 , glioblastoma multiforme (GBM) claim 28 , acute myeloid leukemia (AML) claim 28 , chondrosarcoma claim 28 , intrahepatic cholangiocarcinoma (IHCC) claim 28 , myelodysplastic syndrome (MDS) claim 28 , or myeloproliferative disease (MPD).30. The method of claim 28 , wherein administering is performed orally claim 28 , parentally claim 28 , subcutaneously claim 28 , by injection claim 28 , or by infusion.31. A method of inhibiting mutant isocitrate dehydrogenase comprising administering to a patient in need thereof a compound of .32. A method of reducing 2-hydroxyglutarate comprising administering to a patient in need thereof a compound of .33. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 1 , wherein the cancer is glioma claim 1 , glioblastoma multiforme claim 1 , paraganglioma claim 1 , acute myeloid leukemia (AML) claim 1 , prostate cancer claim 1 , thyroid cancer claim 1 , colon cancer claim 1 , chondrosarcoma claim 1 , cholangiocarcinoma claim 1 , peripheral T-cell lymphoma claim 1 , melanoma claim 1 , intrahepatic cholangiocarcinoma (IHCC) claim 1 , myelodysplastic syndrome (MDS) claim 1 , or myeloproliferative disease (MPD).34. The method of claim 33 , wherein the cancer is glioma claim 33 , glioblastoma multiforme (GBM) claim 33 , acute myeloid leukemia (AML) claim 33 , chondrosarcoma claim 33 , intrahepatic cholangiocarcinoma (IHCC) claim 33 , myelodysplastic syndrome (MDS) claim 33 , or myeloproliferative disease (MPD).35. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 20 , wherein the disease is glioma claim 20 , glioblastoma multiforme claim 20 , paraganglioma claim 20 , acute myeloid leukemia (AML) claim 20 , prostate cancer claim 20 , thyroid cancer claim 20 , colon cancer claim 20 , chondrosarcoma claim 20 , cholangiocarcinoma claim 20 , peripheral T-cell lymphoma claim 20 , melanoma claim 20 , intrahepatic cholangiocarcinoma (IHCC) claim 20 , myelodysplastic syndrome (MDS) claim 20 , or myeloproliferative disease (MPD).36. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 21 , wherein the disease is glioma claim 21 , glioblastoma multiforme claim 21 , paraganglioma claim 21 , acute myeloid leukemia (AML) claim 21 , prostate cancer claim 21 , thyroid cancer claim 21 , colon cancer claim 21 , chondrosarcoma claim 21 , cholangiocarcinoma claim 21 , peripheral T-cell lymphoma claim 21 , melanoma claim 21 , intrahepatic cholangiocarcinoma (IHCC) claim 21 , myelodysplastic syndrome (MDS) claim 21 , or myeloproliferative disease (MPD).37. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 20 , wherein the cancer is glioma claim 20 , glioblastoma multiforme claim 20 , paraganglioma claim 20 , acute myeloid leukemia (AML) claim 20 , prostate cancer claim 20 , thyroid cancer claim 20 , colon cancer claim 20 , chondrosarcoma claim 20 , cholangiocarcinoma claim 20 , peripheral T-cell lymphoma claim 20 , melanoma claim 20 , intrahepatic cholangiocarcinoma (IHCC) claim 20 , myelodysplastic syndrome (MDS) claim 20 , or myeloproliferative disease (MPD).38. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 21 , wherein the cancer is glioma claim 21 , glioblastoma multiforme claim 21 , paraganglioma claim 21 , acute myeloid leukemia (AML) claim 21 , prostate cancer claim 21 , thyroid cancer claim 21 , colon cancer claim 21 , chondrosarcoma claim 21 , cholangiocarcinoma claim 21 , peripheral T-cell lymphoma claim 21 , melanoma claim 21 , intrahepatic cholangiocarcinoma (IHCC) claim 21 , myelodysplastic syndrome (MDS) claim 21 , or myeloproliferative disease (MPD).39. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 1 , wherein the disease is acute myeloid leukemia (AML).40. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 1 , wherein the cancer is acute myeloid leukemia (AML).41. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 20 , wherein the disease is acute myeloid leukemia (AML).42. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 20 , wherein the cancer is acute myeloid leukemia (AML).43. A compound of selected from:6-chloro-7-methoxy-3-{[(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-1,2-dihydroquinolin-2-one;6-chloro-3-{[(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino]methyl}-7-(pyridin-2-ylmethoxy)-1,2-dihydroquinolin-2-one;5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1R)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyrazine-2-carbonitrile;5-{[(1S)-1-(6-chloro-7-methoxy-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-[6-chloro-2-oxo-7-(pyridin-2-ylmethoxy)-1,2-dihydroquinolin-3-yl]ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-{[(1S)-1-{6-chloro-2-oxo-7-[(1R)-1-(pyridin-2-yl)ethoxy]-1,2-dihydroquinolin-3-yl}ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; or5-{[(1S)-1-(6-chloro-8-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.44. A compound of claim 43 , wherein the compound is 6-chloro-7-methoxy-3-{[(1-methyl-2-oxo-1 claim 43 ,2-dihydropyridin-3-yl)amino]methyl}-1 claim 43 ,2-dihydroquinolin-2-one.45. A compound of claim 43 , wherein the compound is 6-chloro-3-{[(1-methyl-2-oxo-1 claim 43 ,2-dihydropyridin-3-yl)amino]methyl}-7-(pyridin-2-ylmethoxy)-1 claim 43 ,2-dihydroquinolin-2-one.46. A compound of claim 43 , wherein the compound is 5-{[(1S)-1-(6-chloro-2-oxo-1 claim 43 ,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1 claim 43 ,6-dihydropyridine-2-carbonitrile.47. A compound of claim 43 , wherein the compound is 5-{[(1S)-1-(6-chloro-2-oxo-1 claim 43 ,2-dihydroquinolin-3-yl)ethyl]amino}-6-oxo-1 claim 43 ,6-dihydropyridine-2-carbonitrile.48. A compound of claim 43 , wherein the compound is 5-{[(1R)-1-(6-chloro-2-oxo-1 claim 43 ,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1 claim 43 ,6-dihydropyridine-2-carbonitrile.49. A compound of claim 43 , wherein the compound is 5-{[(1S)-1-(6-chloro-2-oxo-1 claim 43 ,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1 claim 43 ,6-dihydropyrazine-2-carbonitrile.50. A compound of claim 43 , wherein the compound is 5-{[(1S)-1-(6-chloro-7-methoxy-2-oxo-1 claim 43 ,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1 claim 43 ,6-dihydropyridine-2-carbonitrile.51. A compound of claim 43 , wherein the compound is 5-{[(1S)-1-[6-chloro-2-oxo-7-(pyridin-2-ylmethoxy)-1 claim 43 ,2-dihydroquinolin-3-yl]ethyl]amino}-1-methyl-6-oxo-1 claim 43 ,6-dihydropyridine-2-carbonitrile.52. A compound of claim 43 , wherein the compound is 5-{[(1S)-1-{6-chloro-2-oxo-7-[(1R)-1-(pyridin-2-yl)ethoxy]-1 claim 43 ,2-dihydroquinolin-3-yl}ethyl]amino}-1-methyl-6-oxo-1 claim 43 ,6-dihydropyridine-2-carbonitrile.53. A compound of claim 43 , wherein the compound is 5-{[(1S)-1-(6-chloro-8-fluoro-2-oxo-1 claim 43 ,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1 claim 43 ,6-dihydropyridine-2-carbonitrile.54. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.55. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.56. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.57. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.58. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.59. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.60. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.61. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.62. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.63. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.64. A pharmaceutical composition comprising the compound according to and pharmaceutically acceptable carrier.65. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 43 , wherein the disease is glioma claim 43 , glioblastoma multiforme claim 43 , paraganglioma claim 43 , acute myeloid leukemia (AML) claim 43 , prostate cancer claim 43 , thyroid cancer claim 43 , colon cancer claim 43 , chondrosarcoma claim 43 , cholangiocarcinoma claim 43 , peripheral T-cell lymphoma claim 43 , melanoma claim 43 , intrahepatic cholangiocarcinoma (IHCC) claim 43 , myelodysplastic syndrome (MDS) claim 43 , or myeloproliferative disease (MPD).66. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 44 , wherein the disease is glioma claim 44 , glioblastoma multiforme claim 44 , paraganglioma claim 44 , acute myeloid leukemia (AML) claim 44 , prostate cancer claim 44 , thyroid cancer claim 44 , colon cancer claim 44 , chondrosarcoma claim 44 , cholangiocarcinoma claim 44 , peripheral T-cell lymphoma claim 44 , melanoma claim 44 , intrahepatic cholangiocarcinoma (IHCC) claim 44 , myelodysplastic syndrome (MDS) claim 44 , or myeloproliferative disease (MPD).67. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 45 , wherein the disease is glioma claim 45 , glioblastoma multiforme claim 45 , paraganglioma claim 45 , acute myeloid leukemia (AML) claim 45 , prostate cancer claim 45 , thyroid cancer claim 45 , colon cancer claim 45 , chondrosarcoma claim 45 , cholangiocarcinoma claim 45 , peripheral T-cell lymphoma claim 45 , melanoma claim 45 , intrahepatic cholangiocarcinoma (IHCC) claim 45 , myelodysplastic syndrome (MDS) claim 45 , or myeloproliferative disease (MPD).68. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 46 , wherein the disease is glioma claim 46 , glioblastoma multiforme claim 46 , paraganglioma claim 46 , acute myeloid leukemia (AML) claim 46 , prostate cancer claim 46 , thyroid cancer claim 46 , colon cancer claim 46 , chondrosarcoma claim 46 , cholangiocarcinoma claim 46 , peripheral T-cell lymphoma claim 46 , melanoma claim 46 , intrahepatic cholangiocarcinoma (IHCC) claim 46 , myelodysplastic syndrome (MDS) claim 46 , or myeloproliferative disease (MPD).69. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 47 , wherein the disease is glioma claim 47 , glioblastoma multiforme claim 47 , paraganglioma claim 47 , acute myeloid leukemia (AML) claim 47 , prostate cancer claim 47 , thyroid cancer claim 47 , colon cancer claim 47 , chondrosarcoma claim 47 , cholangiocarcinoma claim 47 , peripheral T-cell lymphoma claim 47 , melanoma claim 47 , intrahepatic cholangiocarcinoma (IHCC) claim 47 , myelodysplastic syndrome (MDS) claim 47 , or myeloproliferative disease (MPD).70. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 48 , wherein the disease is glioma claim 48 , glioblastoma multiforme claim 48 , paraganglioma claim 48 , acute myeloid leukemia (AML) claim 48 , prostate cancer claim 48 , thyroid cancer claim 48 , colon cancer claim 48 , chondrosarcoma claim 48 , cholangiocarcinoma claim 48 , peripheral T-cell lymphoma claim 48 , melanoma claim 48 , intrahepatic cholangiocarcinoma (IHCC) claim 48 , myelodysplastic syndrome (MDS) claim 48 , or myeloproliferative disease (MPD).71. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 49 , wherein the disease is glioma claim 49 , glioblastoma multiforme claim 49 , paraganglioma claim 49 , acute myeloid leukemia (AML) claim 49 , prostate cancer claim 49 , thyroid cancer claim 49 , colon cancer claim 49 , chondrosarcoma claim 49 , cholangiocarcinoma claim 49 , peripheral T-cell lymphoma claim 49 , melanoma claim 49 , intrahepatic cholangiocarcinoma (IHCC) claim 49 , myelodysplastic syndrome (MDS) claim 49 , or myeloproliferative disease (MPD).72. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 50 , wherein the disease is glioma claim 50 , glioblastoma multiforme claim 50 , paraganglioma claim 50 , acute myeloid leukemia (AML) claim 50 , prostate cancer claim 50 , thyroid cancer claim 50 , colon cancer claim 50 , chondrosarcoma claim 50 , cholangiocarcinoma claim 50 , peripheral T-cell lymphoma claim 50 , melanoma claim 50 , intrahepatic cholangiocarcinoma (IHCC) claim 50 , myelodysplastic syndrome (MDS) claim 50 , or myeloproliferative disease (MPD).73. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 51 , wherein the disease is glioma claim 51 , glioblastoma multiforme claim 51 , paraganglioma claim 51 , acute myeloid leukemia (AML) claim 51 , prostate cancer claim 51 , thyroid cancer claim 51 , colon cancer claim 51 , chondrosarcoma claim 51 , cholangiocarcinoma claim 51 , peripheral T-cell lymphoma claim 51 , melanoma claim 51 , intrahepatic cholangiocarcinoma (IHCC) claim 51 , myelodysplastic syndrome (MDS) claim 51 , or myeloproliferative disease (MPD).74. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 52 , wherein the disease is glioma claim 52 , glioblastoma multiforme claim 52 , paraganglioma claim 52 , acute myeloid leukemia (AML) claim 52 , prostate cancer claim 52 , thyroid cancer claim 52 , colon cancer claim 52 , chondrosarcoma claim 52 , cholangiocarcinoma claim 52 , peripheral T-cell lymphoma claim 52 , melanoma claim 52 , intrahepatic cholangiocarcinoma (IHCC) claim 52 , myelodysplastic syndrome (MDS) claim 52 , or myeloproliferative disease (MPD).75. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 53 , wherein the disease is glioma claim 53 , glioblastoma multiforme claim 53 , paraganglioma claim 53 , acute myeloid leukemia (AML) claim 53 , prostate cancer claim 53 , thyroid cancer claim 53 , colon cancer claim 53 , chondrosarcoma claim 53 , cholangiocarcinoma claim 53 , peripheral T-cell lymphoma claim 53 , melanoma claim 53 , intrahepatic cholangiocarcinoma (IHCC) claim 53 , myelodysplastic syndrome (MDS) claim 53 , or myeloproliferative disease (MPD).76. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 43 , wherein the disease is acute myeloid leukemia (AML).77. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 44 , wherein the disease is acute myeloid leukemia (AML).78. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 45 , wherein the disease is acute myeloid leukemia (AML).79. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 46 , wherein the disease is acute myeloid leukemia (AML).80. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 47 , wherein the disease is acute myeloid leukemia (AML).81. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 48 , wherein the disease is acute myeloid leukemia (AML).82. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 49 , wherein the disease is acute myeloid leukemia (AML).83. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 50 , wherein the disease is acute myeloid leukemia (AML).84. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 51 , wherein the disease is acute myeloid leukemia (AML).85. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 52 , wherein the disease is acute myeloid leukemia (AML).86. A method of treating a cell proliferative disease comprising administering to a patient in need thereof a compound of claim 53 , wherein the disease is acute myeloid leukemia (AML).87. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 43 , wherein the cancer is glioma claim 43 , glioblastoma multiforme claim 43 , paraganglioma claim 43 , acute myeloid leukemia (AML) claim 43 , prostate cancer claim 43 , thyroid cancer claim 43 , colon cancer claim 43 , chondrosarcoma claim 43 , cholangiocarcinoma claim 43 , peripheral T-cell lymphoma claim 43 , melanoma claim 43 , intrahepatic cholangiocarcinoma (IHCC) claim 43 , myelodysplastic syndrome (MDS) claim 43 , or myeloproliferative disease (MPD).88. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 44 , wherein the cancer is glioma claim 44 , glioblastoma multiforme claim 44 , paraganglioma claim 44 , acute myeloid leukemia (AML) claim 44 , prostate cancer claim 44 , thyroid cancer claim 44 , colon cancer claim 44 , chondrosarcoma claim 44 , cholangiocarcinoma claim 44 , peripheral T-cell lymphoma claim 44 , melanoma claim 44 , intrahepatic cholangiocarcinoma (IHCC) claim 44 , myelodysplastic syndrome (MDS) claim 44 , or myeloproliferative disease (MPD).89. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 45 , wherein the cancer is glioma claim 45 , glioblastoma multiforme claim 45 , paraganglioma claim 45 , acute myeloid leukemia (AML) claim 45 , prostate cancer claim 45 , thyroid cancer claim 45 , colon cancer claim 45 , chondrosarcoma claim 45 , cholangiocarcinoma claim 45 , peripheral T-cell lymphoma claim 45 , melanoma claim 45 , intrahepatic cholangiocarcinoma (IHCC) claim 45 , myelodysplastic syndrome (MDS) claim 45 , or myeloproliferative disease (MPD).90. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 46 , wherein the cancer is glioma claim 46 , glioblastoma multiforme claim 46 , paraganglioma claim 46 , acute myeloid leukemia (AML) claim 46 , prostate cancer claim 46 , thyroid cancer claim 46 , colon cancer claim 46 , chondrosarcoma claim 46 , cholangiocarcinoma claim 46 , peripheral T-cell lymphoma claim 46 , melanoma claim 46 , intrahepatic cholangiocarcinoma (IHCC) claim 46 , myelodysplastic syndrome (MDS) claim 46 , or myeloproliferative disease (MPD).91. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 47 , wherein the cancer is glioma claim 47 , glioblastoma multiforme claim 47 , paraganglioma claim 47 , acute myeloid leukemia (AML) claim 47 , prostate cancer claim 47 , thyroid cancer claim 47 , colon cancer claim 47 , chondrosarcoma claim 47 , cholangiocarcinoma claim 47 , peripheral T-cell lymphoma claim 47 , melanoma claim 47 , intrahepatic cholangiocarcinoma (IHCC) claim 47 , myelodysplastic syndrome (MDS) claim 47 , or myeloproliferative disease (MPD).92. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 48 , wherein the cancer is glioma claim 48 , glioblastoma multiforme claim 48 , paraganglioma claim 48 , acute myeloid leukemia (AML) claim 48 , prostate cancer claim 48 , thyroid cancer claim 48 , colon cancer claim 48 , chondrosarcoma claim 48 , cholangiocarcinoma claim 48 , peripheral T-cell lymphoma claim 48 , melanoma claim 48 , intrahepatic cholangiocarcinoma (IHCC) claim 48 , myelodysplastic syndrome (MDS) claim 48 , or myeloproliferative disease (MPD).93. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 49 , wherein the cancer is glioma claim 49 , glioblastoma multiforme claim 49 , paraganglioma claim 49 , acute myeloid leukemia (AML) claim 49 , prostate cancer claim 49 , thyroid cancer claim 49 , colon cancer claim 49 , chondrosarcoma claim 49 , cholangiocarcinoma claim 49 , peripheral T-cell lymphoma claim 49 , melanoma claim 49 , intrahepatic cholangiocarcinoma (IHCC) claim 49 , myelodysplastic syndrome (MDS) claim 49 , or myeloproliferative disease (MPD).94. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 50 , wherein the cancer is glioma claim 50 , glioblastoma multiforme claim 50 , paraganglioma claim 50 , acute myeloid leukemia (AML) claim 50 , prostate cancer claim 50 , thyroid cancer claim 50 , colon cancer claim 50 , chondrosarcoma claim 50 , cholangiocarcinoma claim 50 , peripheral T-cell lymphoma claim 50 , melanoma claim 50 , intrahepatic cholangiocarcinoma (IHCC) claim 50 , myelodysplastic syndrome (MDS) claim 50 , or myeloproliferative disease (MPD).95. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 51 , wherein the cancer is glioma claim 51 , glioblastoma multiforme claim 51 , paraganglioma claim 51 , acute myeloid leukemia (AML) claim 51 , prostate cancer claim 51 , thyroid cancer claim 51 , colon cancer claim 51 , chondrosarcoma claim 51 , cholangiocarcinoma claim 51 , peripheral T-cell lymphoma claim 51 , melanoma claim 51 , intrahepatic cholangiocarcinoma (IHCC) claim 51 , myelodysplastic syndrome (MDS) claim 51 , or myeloproliferative disease (MPD).96. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 52 , wherein the cancer is glioma claim 52 , glioblastoma multiforme claim 52 , paraganglioma claim 52 , acute myeloid leukemia (AML) claim 52 , prostate cancer claim 52 , thyroid cancer claim 52 , colon cancer claim 52 , chondrosarcoma claim 52 , cholangiocarcinoma claim 52 , peripheral T-cell lymphoma claim 52 , melanoma claim 52 , intrahepatic cholangiocarcinoma (IHCC) claim 52 , myelodysplastic syndrome (MDS) claim 52 , or myeloproliferative disease (MPD).97. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 53 , wherein the cancer is glioma claim 53 , glioblastoma multiforme claim 53 , paraganglioma claim 53 , acute myeloid leukemia (AML) claim 53 , prostate cancer claim 53 , thyroid cancer claim 53 , colon cancer claim 53 , chondrosarcoma claim 53 , cholangiocarcinoma claim 53 , peripheral T-cell lymphoma claim 53 , melanoma claim 53 , intrahepatic cholangiocarcinoma (IHCC) claim 53 , myelodysplastic syndrome (MDS) claim 53 , or myeloproliferative disease (MPD).98. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 43 , wherein the cancer is acute myeloid leukemia (AML).99. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 44 , wherein the cancer is acute myeloid leukemia (AML).100. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 45 , wherein the cancer is acute myeloid leukemia (AML).101. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 46 , wherein the cancer is acute myeloid leukemia (AML).102. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 47 , wherein the cancer is acute myeloid leukemia (AML).103. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 48 , wherein the cancer is acute myeloid leukemia (AML).104. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 49 , wherein the cancer is acute myeloid leukemia (AML).105. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 50 , wherein the cancer is acute myeloid leukemia (AML).106. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 51 , wherein the cancer is acute myeloid leukemia (AML).107. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 52 , wherein the cancer is acute myeloid leukemia (AML).108. A method of treating a cancer comprising administering to a patient in need thereof a compound of claim 53 , wherein the cancer is acute myeloid leukemia (AML). |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.